SPYRE THERAPEUTICS, INC. Pre-Tax Income
SPYRE THERAPEUTICS, INC. (SYRE) reported Pre-Tax Income of -$36.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$36.20M.
- SPYRE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$69.00M.
- SPYRE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$62.53M.
- SPYRE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$11.18M.
- SPYRE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$155.22M.
- SPYRE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$207.97M.
- SPYRE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$338.82M.
- SPYRE THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$83.95M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.20M 10-Q · filed 2026-08-04 | -$105.20M 10-Q · filed 2026-08-04 | -$167.74M derived: sum of 3 quarters · filed 2026-08-04 | -$178.92M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$69.00M 10-Q · filed 2026-05-05 | -$131.53M derived: sum of 2 quarters · filed 2026-05-05 | -$142.72M derived: sum of 3 quarters · filed 2026-05-05 | -$179.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$62.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$73.71M derived: sum of 2 quarters · filed 2026-02-19 | -$110.43M derived: sum of 3 quarters · filed 2026-08-04 | -$155.22M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$11.18M 10-Q · filed 2025-11-04 | -$47.90M derived: sum of 2 quarters · filed 2026-08-04 | -$92.69M 10-Q · filed 2025-11-04 | -$148.98M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$36.72M 10-Q · filed 2026-08-04 | -$81.50M 10-Q · filed 2026-08-04 | -$137.80M derived: sum of 3 quarters · filed 2026-08-04 | -$206.81M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$44.79M 10-Q · filed 2026-05-05 | -$101.08M derived: sum of 2 quarters · filed 2026-05-05 | -$170.09M derived: sum of 3 quarters · filed 2026-05-05 | -$208.93M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$56.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$125.31M derived: sum of 2 quarters · filed 2026-02-19 | -$164.14M derived: sum of 3 quarters · filed 2026-02-19 | -$207.97M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$69.01M 10-Q · filed 2025-11-04 | -$107.85M derived: sum of 2 quarters · filed 2025-11-04 | -$151.67M 10-Q · filed 2025-11-04 | -$214.85M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$38.84M 10-Q · filed 2025-08-05 | -$82.66M 10-Q · filed 2025-08-05 | -$145.84M derived: sum of 3 quarters · filed 2026-02-19 | -$185.95M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$43.83M 10-Q · filed 2025-05-08 | -$107.00M derived: sum of 2 quarters · filed 2026-02-19 | -$147.11M derived: sum of 3 quarters · filed 2026-02-19 | -$364.18M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$63.18M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | -$103.28M derived: sum of 2 quarters · filed 2026-02-19 | -$320.36M derived: sum of 3 quarters · filed 2026-02-19 | -$338.82M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$40.10M 10-Q/A · filed 2024-11-18 | -$257.18M derived: sum of 2 quarters · filed 2024-11-18 | -$275.64M 10-Q/A · filed 2024-11-18 | -$294.42M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$217.07M 10-Q/A · filed 2024-11-18 | -$235.53M 10-Q/A · filed 2024-11-18 | -$254.32M derived: sum of 3 quarters · filed 2025-02-27 | -$272.76M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$18.46M 10-Q/A · filed 2024-11-18 | -$37.24M derived: sum of 2 quarters · filed 2025-02-27 | -$55.69M derived: sum of 3 quarters · filed 2025-02-27 | -$78.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$18.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$37.23M derived: sum of 2 quarters · filed 2025-02-27 | -$59.54M derived: sum of 3 quarters · filed 2025-02-27 | -$83.95M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$18.44M 10-Q · filed 2023-11-09 | -$40.76M derived: sum of 2 quarters · filed 2023-11-09 | -$65.17M 10-Q · filed 2023-11-09 | -$85.62M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | -$22.31M 10-Q · filed 2023-08-11 | -$46.72M 10-Q · filed 2023-08-11 | -$67.17M derived: sum of 3 quarters · filed 2024-11-18 | -$87.45M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | -$24.44M 10-Q · filed 2023-05-11 | -$44.86M derived: sum of 2 quarters · filed 2024-11-18 | -$65.14M derived: sum of 3 quarters · filed 2024-11-18 | -$71.88M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | -$20.42M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | -$40.70M derived: sum of 2 quarters · filed 2024-11-18 | -$47.44M derived: sum of 3 quarters · filed 2024-11-18 | -$65.66M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | -$20.28M 10-Q · filed 2022-11-03 | -$27.02M derived: sum of 2 quarters · filed 2022-11-03 | -$45.24M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$6.74M 10-Q · filed 2022-08-04 | -$24.96M 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | -$22.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$40.75M derived: sum of 2 quarters · filed 2023-03-02 | -$62.16M derived: sum of 3 quarters · filed 2023-03-02 | -$80.89M 10-K · filed 2023-03-02 |
| 2020-09-30 | -$18.03M 10-Q · filed 2021-11-04 | -$39.45M derived: sum of 2 quarters · filed 2021-11-04 | -$58.18M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$21.42M 10-Q · filed 2021-08-05 | -$40.15M 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | -$78.25M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |